Alzheimer's Disease Beyond Abeta.
Many of the Alzheimer's disease (AD) clinical trials have made it far enough down the pipeline to allow conclusions about targeting the amyloid-beta peptide (Abeta) as a therapeutic approach. Based on these results, it is becoming clear that a multifocal approach to AD treatment is probably necessary. However, critical discussion beyond Abeta is necessary to enable the next wave of AD therapeutic targets. For this reason, the 2010 Keystone Symposium, 'Alzheimer's Disease Beyond Abeta', was organized by JoAnne McLaurin and Tony Wyss-Coray to spark topical discussion and debate. While researchers struggled to get beyond that ever-present pathognomonic feature of AD, new and exciting evidence was presented that raised our awareness of what is around the corner for next-generation AD therapeutics beyond Abeta. This report will describe some of the highlights from Copper Mountain Resort throughout the meeting period of 10-15 January 2010 in Colorado (USA). Despite illuminating scientific presentations and intense discussions, a number of important questions remain concerning the best biomarkers and targets to focus on, and when and how to therapeutically intervene.
Town
Terrence
T
Department of Biomedical Sciences, Regenerative Medicine Institute, Cedars-Sinai Medical Center, SSB3 Room 361, Los Angeles, CA 90048, USA. terrence.town@cshs.org
D000544:Alzheimer Disease / Q000378:metabolism* / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D006801:Humans
D016229:Amyloid beta-Peptides; D015415:Biomarkers